The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.

The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.

Methods for stabilizing or encapsulating at least one compound selected from the group consisting of nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), derivatives thereof, or salts thereof, are provided. Compositions including wax prills, stabilized, or encapsulated forms of at least one compound selected from the group consisting of nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, are also provided.

Various embodiments of health supplements for mammals are disclosed. The health supplement consists of one or more metabolite ingestion components; anti-inflammatory components; and oral absorption components. The metabolite ingestion component includes green-lipped mussel powder in an amount between 1-5 mg/kg of body weight. The anti-inflammatory component includes cinnamon powder in an amount between 0.1-1. mg/kg of body weight; ascorbic acid powder; turmeric powder present in an amount between 0.1-1.0 mg/kg of body weight; Piper nigrum powder in an amount between 0.05-0.2 mg/kg of body weight; and the oral absorption component includes diatomaceous earth powder and molasses powder. The metabolite ingestion component includes sea cucumber powder, sodium hyaluronate powder, methylsylfonylmethane powder, and creatine monohydrate powder. The anti-inflammatory component includes Boswellia serrata powder, Harpagophytum procumbens powder, and calcined curcumin powder. The oral absorption component includes Lactobacillus probiotic powder; and calcined dolomite powder.

Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.

The olive leaf extract silver nanoparticles may be synthesized by extracting olive leaves and using the extract to synthesize AgNPs. Olive leaves may be washed, dried, and ground to a powder. The olive leaf powder may be mixed with a first solvent to form a first olive leaf extract. The first olive leaf extract may then be separated and/or concentrated by centrifugation and filtration to form a filtrate. The filtrate may be evaporated to form a residue. The residue may then be resuspended in ethanol to form a second olive leaf extract. The second olive leaf extract may be mixed with AgNO.sub.3 to form a mixture including the AgNPs.

Mixed allergen compositions of two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.

Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.

The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37 C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.